Cell biology and biochemistry of acid β -glucosidase: The gaucher disease enzyme

Gaucher Disease

Volumn , Issue , 2006, Pages 49-66

  Grabowski, Gregory A ^a   Kazimierczuk, Andrzej ^a   Liou, Benjamin ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 53049098754     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420005509     Document Type: Chapter

References (89)

1. Beutler, E. and Grabowski, G.A., Gaucher disease, in The Metabolic and Molecular Bases of Inherited Diseases, 8th ed., Scriver, C.R., Beaudet, A.L., Sly, W.S., and Valle, D. Eds., McGraw-Hill, New York, 2001, 3635.
2. Ponce, E. et al., Temporal and spatial expression of murine acid β-glucosidase mRNA, Mol. Genet. Metab. 74, 426, 2001.
3. Wong, K. et al., Neuropathology provides clues to the pathophysiology of Gaucher disease, Mol. Genet. Metab. 82, 192, 2004.
4. Kaye, E.M. et al., Type 2 and type 3 Gaucher disease: a morphological and biochemical study, Ann. Neurol. 20, 223, 1986.
5. Xu, Y.H., Busald, C., and Grabowski, G.A., Reconstitution of TCP80/NF90 translation inhibition activity in insect cells, Mol. Genet. Metab. 70, 106, 2000.
6. Xu, Y.H. and Grabowski, G.A., Molecular cloning and characterization of a translational inhibitory protein that binds to coding sequences of human acid β-glucosidase and other mRNAs, Mol. Genet. Metab. 68, 441, 1999.
7. Xu, Y.H. and Grabowski, G.A., Translational inefficiency of acid β-glucosidase mRNA in transgenic mammalian cells, Mol. Genet. Metab. 64, 87, 1998.
8. Sorge, J.A. et al., The human glucocerebrosidase gene has two functional ATG initiator codons, Am. J. Hum. Genet. 41, 1016, 1987.
9. Sorge, J. et al., Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA, Proc. Natl. Acad. Sci. U.S.A., 82, 7289, 1985.
10. Edmunds, T., Glucocerebrosidase: Ceredase and Cerezyme, in Directory of Therapeutic Enzymes, Walsh, M. Ed., Taylor & Francis, Boca Raton, FL, 2005.
11. Berg-Fussman, A. et al., Human β-glucosidase: N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity, J. Biol. Chem., 268, 14861, 1993.
12. Grace, M.E. and Grabowski, G.A., Human acid β-glucosidase: Glycosylation is required for catalytic activity, Biochem. Biophys. Res. Commun., 168, 771, 1990.
13. Takasaki, S. et al., Structure of the N-asparagine-linked oligosaccharide units of human placental β-glucocerebrosidase, J. Biol. Chem., 259, 10112, 1984.
14. Fiete, D., Beranek, M.C. and Baenziger, J.U., The macrophage/endothelial cell mannose receptor cDNA encodes a protein that binds oligosaccharides terminating with SO4-4-GalNAcb1,4GlcNAcb or Man at independent sites, Proc. Natl. Acad. Sci. U.S.A., 94, 11256, 1997.
15. Pontow, S.E., Kery, V., and Stahl, P.D., Mannose receptor, Int. Rev. Cytol., 137, 221, 1997.
16. Lee, S.J. et al., Mannose receptor-mediated regulation of serum glycoprotein homeostasis, Science. 295, 1898, 2002.
17. Bergmann, J.E. and Grabowski, G.A., Posttranslational processing of human lysosomal acid β-glucosidase: a continuum of defects in Gaucher disease type 1 and type 2 fibroblasts, Am. J. Hum. Genet. 44, 741, 1989.
18. Erickson, A.H., Ginns, E.I., and Barranger, J.A., Biosynthesis of the lysosomal enzyme glucocerebrosidase, J. Biol. Chem., 260, 14319, 1985.
19. Sun, Y., Qi, X., and Grabowski, G.A., Saposin C is required for normal resistance of acid β-glucosidase to proteolytic degradation, J. Biol. Chem. 278, 31918, 2003.
20. Salvioli, R. et al., Glucosylceramidase mass and subcellular localization are modulated by cholesterol in Niemann-Pick disease type C, J. Biol. Chem. 279, 17674, 2004.
21. Leonova, T. and Grabowski, G.A., Fate and sorting of acid β-glucosidase in transgenic mammalian cells, Mol. Genet. Metab. 70, 281, 2000.
22. Grabowski, G.A., Unpublished observation, 2005.
23. Liu, C. et al., Long-term expression and secretion of human glucocerebrosidase by primary murine and human myoblasts and differentiated myotubes, J. Mol. Med., 76, 773, 1998.
24. Beutler, E., Kuhl, W., and Sorge, J., Cross-reacting material in Gaucher disease fibroblasts, Proc. Natl. Acad. Sci. U.S.A. 81, 6506, 1984.
25. Beutler, E., Kuhl, W., and Sorge, J., Glucocerebrosidase “processing” and gene expression in various forms of Gaucher disease, Am. J. Hum. Genet. 37, 1062, 1985.
26. Martin, B.M. et al., Glycosylation and processing of high levels of active human glucocerebrosidase in invertebrate cells using a baculovirus expression vector, DNA 7, 99, 1988.
27. Zimmer, K.P. et al., Intracellular transport of acid β-glucosidase and lysosomeassociated membrane proteins is affected in Gaucher’s disease (G202R mutation), J. Path. 188, 407, 1999.
28. Zhao, H. et al., Gaucher’s disease: identification of novel mutant alleles and genotypephenotype relationships, Clin. Genet. 64, 57, 2003.
29. Schmitz, M. et al., Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher’s disease, Int. J. Biochem. Cell. Biol. 37, 2310, 2005.
30. Ron, I. and Horowitz, M., ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity, Hum. Mol. Genet. 14, 2387, 2005.
31. Bijsterbosch, M.K. et al., Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase. Predominant uptake by liver endothelial cells, Eur. J. Biochem., 237, 344, 1996.
32. Xu, Y.H. et al., Turnover and distribution of intravenously administered mannoseterminated human acid β-glucosidase in murine and human tissues, Pediatr. Res. 39, 313, 1996.
33. Murray, G.J. and Jin, F-S., Immunoelectron microscopic localization of mannoseterminal glucocerebrosidase in lysosomes of rat liver Kupffer cells, J. Histochem. Cytochem. 43, 149, 1995.
34. Horowitz, M. et al., The human glucocerebrosidase gene and pseudogene: structure and evolution, Genomics. 4, 87, 1989.
35. Ginns, E.I. et al., Gene mapping and leader polypeptide sequence of human glucocerebrosidase: implications for Gaucher disease, Proc. Natl. Acad. Sci. U.S.A., 82, 7101, 1985.
36. Miao, S. et al., Identification of Glu340 as the active site nucleophile in human glucocerebrosidase by use of electrospray tandem mass spectrometry, J. Biol. Chem. 269, 10975, 1994.
37. Liou, B., Mechanistic studies of normal and mutant acid β-glucosidases, M.S., University of Cincinnati, 1996.
38. Maret, A. et al., Modifications of the molecular weight of membrane-bound nonspecific β-glucosidase in type 1 Gaucher disease determined in situ by the radiation inactivation method, Biochim. Biophys. Acta., 799, 91, 1984.
39. Maret, A. et al., Modification of subunit interaction in membrane-bound acid β-glucosidase from Gaucher disease, FEBS Lett., 160, 93, 1983.
40. Salvayre, R. et al., Comparative properties of the three groups of splenic β-glucosidase molecular forms, Prog. Clin. Biol. Res., 95, 443, 1982.
41. Maret, A. et al., Properties of the molecular forms of β-glucosidase and β-glucocerebrosidase from normal human and Gaucher disease spleen. Eur. J. Biochem., 115, 455, 1981 (in French, author’s translation).
42. Grace, M.E. et al., Analyses of catalytic activity and inhibitor binding of human acid β-glucosidase by site-directed mutagenesis. Identification of residues critical to catalysis and evidence for causality of two Ashkenazi Jewish Gaucher disease type 1 mutations, J. Biol. Chem. 265, 6827, 1990.
43. Grace, M.E. et al., Analysis of human acid β-glucosidase by site-directed mutagenesis and heterologous expression, J. Biol. Chem. 269, 2283, 1994.
44. Paal, K., Ito, M., and Withers, S.G., Paenibacillus sp. TS12 glucosylceramidase: kinetic studies of a novel sub-family of family 3 glycosidases and identification of the catalytic residues, Biochem. J. 378, 141, 2004.
45. Kempton, J.B. and Withers, S.G., Mechanism of Argobacterium β-glucosidase: kinetic studies, Biochemistry. 31, 9961, 1992.
46. Withers, S.G. et al., Mechanistic consequences of mutation of the active site nucleophile Glu358 in Argobacterium β-glucosidase, Biochemistry. 31, 9979, 1992.
47. Grace, M.E. et al., Non-pseudogene-derived complex acid β-glucosidase mutations causing mild type 1 and severe type 2 gaucher disease, J. Clin. Invest., 103, 817, 1999.
48. Amaral, O. et al., Gaucher disease: expression and characterization of mild and severe acid β-glucosidase mutations in Portuguese type 1 patients, Eur. J. Hum. Genet., 8, 95, 2000.
49. Henrissat, B. et al., Conserved catalytic machinery and the prediction of a common fold for several families of glycosyl hydrolases, Proc. Natl. Acad. Sci. U.S.A., 92, 7090, 1995.
50. Ohashi, T. et al., Characterization of human glucocerebrosidase from different mutant alleles, J. Biol. Chem. 266, 3661, 1991.
51. Grace, M.E. et al., Gaucher disease: heterologous expression of two alleles associated with neuronopathic phenotypes, Am. J. Hum. Genet. 49, 646, 1991.
52. Dvir, H. et al., X-ray structure of human acid-β-glucosidase, the defective enzyme in Gaucher disease, EMBO, Rep 4, 704, 2003.
53. Premkumar, L. et al., X-ray structure of human acid β-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease, J. Biol. Chem. 280, 23815, 2005.
54. Davies, G.J., Ducros, V.M-A., and Zechel, D.I., Mapping the conformational itinerary of b-glycosidase by x-ray crystallography, Biochem. Soc. Trans., 31, 523, 2003.
55. Grabowski, G.A., Gatt, S., and Horowitz, M., Acid β-glucosidase: enzymology and molecular biology of Gaucher disease, Crit. Rev. Biochem. Mol. Biol., 25, 385, 1990.
56. Ho, M.W. et al., Glucocerebrosidase: reconstitution of activity from macromolecular components, Biochem. J., 131, 173, 1973.
57. Dale, G.L. et al., Large scale purification of glucocerebrosidase from human placentas, Birth Defects. 16, 33, 1980.
58. Berent, S.L. and Radin, N.S., Mechanism of activation of glucocerebrosidase by co-β-glucosidase (glucosidase activator protein), Biochim. Biophys. Acta., 664, 572, 1981.
59. Sarmientos, F., Schwarzmann, G., and Sandhoff, K., Specificity of human glucosylceramide β-glucosidase towards synthetic glucosphingolipids inserted into liposomes. Kinetic studies in a detergent-free assay system, Eur. J. Biochem. 160, 527, 1986.
60. Christomanou, H. et al., Activator protein deficient Gaucher’s disease. A second patient with the newly identified lipid storage disorder, Klin Wochenschr. 67, 999, 1989.
61. Christomanou, H., Aignesberger, A., and Linke, R.P., Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant, Biol. Chem. Hoppe. Seyler., 367, 879, 1986.
62. Qi, X. and Grabowski, G.A., Acid β-glucosidase: intrinsic fluorescence and conformational changes induced by phospholipids and saposin C, Biochemistry. 37, 11544, 1998.
63. Qi, X. and Grabowski, G.A., Molecular and cell biology of acid β-glucosidase and prosaposin, Prog. Nucl. Acid. Res. Mol. Biol., 66, 203, 2001.
64. Vaccaro, A.M. et al., pH-Dependent conformational properties of saposins and their interations with phospholipid membranes, J. Biol. Chem. 270, 30576, 1995.
65. Qi, X. et al., Functional organization of saposin C: definition of the neurotrophic and acid β-glucosidase activation regions, J. Biol. Chem. 271, 6874, 1996.
66. Vaccaro, A.M. et al., Saposin C induces pH-dependent destabilization and fusion of phosphatidylserine-containing vesicles, FEBS Lett. 349, 181, 1994.
67. Wilkening, G., Linke, T., and Sandhoff, K., Lysosomal degradation on vesicular membrane surfaces. Enhanced glucosylceramide degradation by lysosomal anionic lipids and activators, J. Biol. Chem. 273, 30271, 1998.
68. Sarmientos, F., Schwarzmann, G., and Sandhoff, K., Direct evidence by carbon-13 NMR spectroscopy for the erythro configuration of the sphingoid moiety in Gaucher cerebroside and other natural sphingolipids, Eur. J. Biochem. 146, 59, 1985.
69. Nilsson, O. and Svennerholm, L., Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease, J. Neurochem., 39, 709, 1982.
70. Nilsson, O. and Svennerholm, L., Characterization and quantitative determination of gangliosides and neutral glycosphingolipids in human liver, J. Lipid Res., 23, 327, 1982.
71. Nilsson, O. et al., The occurrence of psychosine and other glycolipids in spleen and liver from the three major types of Gaucher’s disease, Biochim. Biophys. Acta., 712, 453, 1982.
72. Vaccaro, A.M., Kobayashi, T., and Suzuki, K., Comparison of synthetic and natural glucosylceramides as substrate for glucosylceramidase assay, Clin. Chim. Acta., 118, 1, 1982.
73. Vaccaro, A.M., Muscillo, M., and Suzuki, K., Characterization of human glucosylsphingosine glucosyl hydrolase and comparison with glucosylceramidase, Eur. J. Biochem. 146, 315, 1985.
74. Osiecki-Newman, K. et al., Human acid β-glucosidase: use of inhibitors, alternative substrates and amphiphiles to investigate the properties of the normal and Gaucher disease active sites, Biochim. Biophys. Acta., 915, 87, 1987.
75. Grabowski, G.A., Gaucher disease: gene frequencies and genotype/phenotype correlations, Genet. Test., 1, 5, 1997.
76. Sarmientos, F., Schwarzmann, G., and Sandhoff, K., Specificity of human glucosylceramide β-glucosidase towards synthetic glucosylsphingolipids inserted into liposomes. Kinetic studies in a detergent-free assay system, Eur. J. Biochem. 160, 527, 1986.
77. Fluharty, C.B. et al., Comparative lipid binding study on the cerebroside sulfate activator (Saposin B), J. Neurosci. Res., 63, 82, 2001.
78. Ahn, V.E. et al., Crystal structure of saposin B reveals a dimeric shell for lipid binding, Proc. Natl. Acad. Sci. U.S.A., 100, 38, 2003.
79. Van Paridon, P.A., Visser, A.J., and Wirtz, K.W., Binding of phospholipids to the phosphatidylinositol transfer protein from bovine brain as studied by steady-state and time-resolved fluorescence spectroscopy, Biochim. Biophys. Acta., 898, 172, 1987.
80. Greenberg, P. et al., Human acid β-glucosidase: use of sphingosyl and N-alkylglucosylamine inhibitors to investigate the properties of the active site, Biochim. Biophys. Acta., 1039, 12, 1990.
81. Theophilus, B. et al., Gaucher disease: molecular heterogeneity and phenotypegenotype correlations, Am. J. Hum. Genet. 45, 212, 1989.
82. Latham, T. et al., Complex alleles of the acid β-glucosidase gene in Gaucher disease, Am. J. Hum. Genet. 47, 79, 1990.
83. Gonzales, M.L. et al., Activation of human spleen glucocerebrosidases by monoacylglycol sulfates and diacylglycerol sulfates, Arch. Biochem. Biophys., 262, 345, 1988.
84. Basu, A. et al., Activators of spleen glucocerebrosidase from controls and patients with various forms of Gaucher’s disease, J. Biol. Chem. 259, 1714, 1984.
85. Glew, R.H. et al., Enzymic differentiation of neurologic and nonneurologic forms of Gaucher’s disease, J. Neuropathol. Exp. Neurol., 41, 630, 1982.
86. Sawkar, A.R. et al., Chemical chaperones increase the cellular activity of N370S β-glucosidase: a therapeutic strategy for Gaucher disease, Proc. Natl. Acad. Sci. U.S.A., 99, 15428, 2002.
87. Osiecki-Newman, K. et al., Human acid β-glucosidase: inhibition studies using glucose analogues and pH variation to characterize the normal and Gaucher disease glycon binding sites, Enzyme 40, 173, 1988.
88. Bedarkar, S. et al., Crystallization and preliminary x-ray diffraction analysis of the catalytic domain of Cex, an exo-β-1,4-glucanase and β-1, 4-xylanase from the bacterium Cellulomonas fimi, J. Mol. Biol., 228, 693, 1992.
89. Liou, B. et al., Analyses of variant acid β-glucosidases: effects of Gaucher disease mutaitons, J. Biol. Chem. 281, 4242, 2006.